News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer
Photo from sukruyazar.com
Jul 20, 2024, 10:37

Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer

Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:

”ANTHER Trial Results: Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer. At a 10.3-year follow-up, dose-dense treatment showed:

  • Better recurrence-free survival (HR 0.80; P = 0.030). 
  • Better event-free survival (HR 0.78; P = 0.009). 
  • Improved distant disease-free survival (HR 0.79; P = 0.030).
  • There was no significant difference in overall survival (HR 0.82; P = 0.109).

Dose-dense regimens significantly improve breast cancer-free survival and disease-free survival compared to standard chemotherapy.”

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Authors: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis, Jonas Bergh.

Ivan R. Gonzalez

Source: Ivan R. Gonzalez/X

adjuvant chemotherapy Alexios Matikas Anne Andersson Breast Cancer cancer Günther G. Steger Hemming Johansson Iván R. González Jonas Bergh Mats Hellström Michael Gnant Michael Untch OncoDaily Oncology Per Malmström Richard Greil Sabine Schmatloch Sibylle Loibl Theodoros Foukakis Tommy Fornander Volker Möbus Yvonne Brandberg
Special Coverage
Blog
Jan 20, 2025, 20:33
Jame Abraham: Proud to be part of Top Accruing LAPS NRG oncology trials
Blog
Jan 20, 2025, 20:31
Health in the age of disinformation - The Lancet
Blog
Jan 20, 2025, 20:29
Shilpa Gupta: Improving the lives of patients with bladder cancer with a multi-disciplinary and personalized approach
Blog
Jan 20, 2025, 20:28
Mikayel Arustamyan: Seeking Oncology Professionals for Leadership and Management Roles
Blog
Jan 20, 2025, 20:26
Universal Assessment and Intervention for Psychosocial Care Standards - SIOP
Blog
Jan 20, 2025, 20:23
Douglas Flora: What if professional insights could directly fuel life-changing impact?
Blog
Jan 20, 2025, 20:21
Zeina Nahleh: Best of ⁦SABCS with practice changing advances in breast cancer
Blog
Jan 20, 2025, 20:12
Active Symptom Monitoring for Premenopausal Women in Breast Cancer Therapy
Blog
Jan 20, 2025, 20:10
Yvonne Bombard: Expanding Definitions of Medically Actionable Genomic Results
Blog
Jan 20, 2025, 20:08
The Lancet Highlights Dangers of Disinformation in Health
Blog
Jan 20, 2025, 20:06
Emad Shash: Public-Private Partnership to Revolutionize Patient Care
Blog
Jan 20, 2025, 20:03
Alpa Patel: American Cancer Society Releases 2025 Cancer Facts and Figures